Aviva plc (LON:AV)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 21.19B +3.3% |
| Revenue (ttm) | 30.77B +26.8% |
| Net Income | 559.00M -14.2% |
| EPS | 0.18 -17.7% |
| Shares Out | 2.99B |
| PE Ratio | 39.32 |
| Forward PE | 10.91 |
| Dividend | 0.39 (5.55%) |
| Ex-Dividend Date | Sep 3, 2026 |
| Volume | 4,095,177 |
| Open | 703.40 |
| Previous Close | 713.00 |
| Day's Range | 703.40 - 713.00 |
| 52-Week Range | 590.60 - 740.60 |
| Beta | 0.64 |
| Analysts | Buy |
| Price Target | 733.41 (+3.5%) |
| Est. Earnings | Nov 12, 2026 |
About Aviva
Aviva plc provides various insurance, retirement, and wealth products in the United Kingdom, Ireland, Canada, India, and China. It operates through General Insurance; Insurance, Wealth & Retirement; Aviva Investors; and International Investments segments. The company offers gadget, home, motor, pet, and health insurance, as well as commercial, specialty insurance and protection. It also provides life insurance, long-term health and accident insurance, savings, pension, and annuity products, as well as pension fund and lifetime mortgage products... [Read more]
Financial Performance
In 2025, Aviva's revenue was 28.68 billion, an increase of 26.11% compared to the previous year's 22.74 billion. Earnings were 767.00 million, an increase of 21.17%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for AV stock is "Buy." The 12-month stock price target is 733p, which is an increase of 3.50% from the latest price.
News
Aviva Transcript: Investor update
Wealth assets reached GBP 261bn, with nearly GBP 30bn of organic flows over three years; targets remain GBP 280m operating profit by 2027 and >GBP 500m by 2032. Growth is driven by Workplace and Adviser Platform, with further opportunity in Direct Wealth, advice and AI-enabled services.
Aviva Press release: Investor update
Aviva issued a press release on October 16, 2026, disclosing material business information to investors.
Aviva Slides: Investor update
Aviva has posted slides in relation to its latest quarterly earnings report, which was published on October 16, 2026.
Aviva price target raised to 721 GBp from 671 GBp at Citi
Citi analyst James Shuck raised the firm’s price target on Aviva (AIVAF) to 721 GBp from 671 GBp and keeps a Neutral rating on the shares.
Aviva price target raised to 815 GBp from 800 GBp at JPMorgan
JPMorgan raised the firm’s price target on Aviva (AIVAF) to 815 GBp from 800 GBp and keeps an Overweight rating on the shares.
Aviva upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Farooq Hanif upgraded Aviva (AIVAF) to Overweight from Neutral with a price target of 800 GBp, up from 715 GBp. The firm adjusted ratings in the UK life…
Aviva Earnings Call Transcript: H1 2026
Strong H1 2026 results with 24% operating profit growth, robust capital position, and successful Direct Line integration. Wealth and GI segments delivered double-digit growth, while AI and digital investments drive efficiency. Confident in exceeding three-year and long-term targets.
Aviva Slides: H1 2026
Aviva has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 14, 2026.
Aviva Quarterly report: H1 2026
Aviva has published its H1 2026 quarterly earnings report on August 14, 2026.
Aviva Posts Strong First-Half Profit Growth
The insurer and asset manager's operating profit rose in the first half, though it cut its full-year expectations for its health business.
UK's Aviva takes full ownership of India unit after New Delhi eases foreign investment rules
British insurer Aviva said on Thursday it had agreed to buy the remaining 26% stake in its Indian life insurance joint venture from local partner Dabur Invest Corp, taking full ownership of the bu...
Aviva price target raised to 680 GBp from 670 GBp at Morgan Stanley
Morgan Stanley raised the firm’s price target on Aviva (AIVAF) to 680 GBp from 670 GBp and keeps an Equal Weight rating on the shares.
Aviva detects record £230m in bogus insurance claims as use of AI rises
Insurer found 18,400 suspect claims last year with some scammers using AI to fake accident scenes and documents
Aviva price target lowered to 715 GBp from 725 GBp at JPMorgan
JPMorgan lowered the firm’s price target on Aviva (AIVAF) to 715 GBp from 725 GBp and keeps a Neutral rating on the shares.
Aviva initiated with a Buy at Berenberg
Berenberg initiated coverage of Aviva (AIVAF) with a Buy rating and 800 GBp price target The insurer is among the few scale players capturing the “growing pool” of UK retirement…
Aviva Earnings Call Transcript: Q1 2026
Strong Q1 growth with general insurance premiums up 19% and Wealth net flows up 49% year-over-year. Direct Line integration is on track, with improved profitability and capital synergies expected by year-end. Solvency remains robust at 171%.
Aviva Earnings release: Q1 2026
Aviva released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Aviva Posts Rise in Insurance Premiums
The insurer and asset manager's quarterly general insurance premiums reached £3.4 billion, up 19% compared with a year prior.
Aviva downgraded to Hold from Buy at Jefferies
Jefferies downgraded Aviva (AIVAF) to Hold from Buy with a price target of 637 GBp, up from 560 GBp. The firm sees a balanced risk/reward at current share levels with…
Aviva price target raised to 765 GBp from 760 GBp at Deutsche Bank
Deutsche Bank analyst Kailesh Mistry raised the firm’s price target on Aviva (AIVAF) to 765 GBp from 760 GBp and keeps a Buy rating on the shares. Published first on…
Aviva Earnings Call Transcript: Q4 2025
Delivered strong growth with operating profit up 25%, EPS at 56p, and a 10% dividend increase. Achieved 2026 targets early, raised ambitions, and advanced Direct Line integration, with robust performance across all segments and continued investment in AI and efficiency.
Aviva Annual report: Q4 2025
Aviva has published its Q4 2025 annual report on March 5, 2026.
Aviva Annual report: Q4 2025
Aviva has published its Q4 2025 annual report on March 5, 2026.
Aviva Slides: Q4 2025
Aviva has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 5, 2026.
Aviva Bio Announces FDA Guidance on Development Pathway for Women's Testosterone Therapy and New Evidence of a Reduced Risk of Breast Cancer Cell Proliferation for AVA-291
CONCORD, Mass.--(BUSINESS WIRE)--Aviva Bio received FDA guidance on women's testosterone and reported new data showing AVA-291's markedly reduced breast cancer cell proliferation.